News
Author: admin als-handoff
-
Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards
SEATTLE, Wash. and VANCOUVER, British Columbia, August 13, 2021 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has expanded its Clinical Operations Team with the hiring of a Director of Clinical Operations,…
-
Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update
SEATTLE, Wash and VANCOUVER, British Columbia, August 12, 2021 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced second quarter 2021 financial results and provided an update on the cytisinicline clinical development program. Recent Events &…
-
Achieve Announces Two Patents Granted by USPTO for Novel Cytisinicline Dosing and Administration Regimen
SEATTLE, Wash and VANCOUVER, British Columbia, August 11, 2021 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,083,715 and U.S. Patent…
-
Achieve Life Sciences to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 12, 2021
SEATTLE, Wash. and VANCOUVER, British Columbia / ACCESSWIRE / August 3, 2021 / Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its second quarter 2021 financial results and provide an update on the cytisinicline development program on Thursday, August 12, 2021 at…
-
Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use
SEATTLE, Wash and VANCOUVER, British Columbia, July 22, 2021 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA) of the National…